share_log

Empower Clinics Subsidiary to Launch Cardiology Services With Significantly Reduced Wait Times for Result

Empower Clinics Subsidiary to Launch Cardiology Services With Significantly Reduced Wait Times for Result

授權診所子公司推出心臟病服務,大幅縮短等待結果的時間
Accesswire ·  2022/11/17 22:05

The Medi-Collective to offer new specialty services in partnership with two leading Ontario cardiology companies

Medi-Collective將與安大略省兩家領先的心臟病公司合作提供新的專科服務

VANCOUVER, BC / ACCESSWIRE / November 17, 2022 / EMPOWER CLINICS INC (CSE:EPW)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, a medical device company and a high complexity medical diagnostics laboratory - today announced that. The Medi-Collective signed a Memorandum of Understanding ("MOU") to develop and launch a program for cardiology services and testing in partnership with Heart Wellness Cardiac Clinics (HWCC) and their subsidiary Holter Health (HH).

温哥華,BC/ACCESSWIRE/2022年11月17日/Empower Clinics Inc.(CSE:EPW)(OTCQB:EPWCF)("增強能力“或”公司“)一家綜合醫療保健公司--通過醫療中心、一家醫療器械公司和一家高度複雜的醫療診斷實驗室為患者提供服務--今天宣佈。Medi-Collective簽署了一份諒解備忘錄(MOU),與心臟健康心臟診所(HWCC)及其子公司Holter Health(HH)合作開發和推出一項心臟病服務和測試計劃。

The cardiology services will include, and are not limited to, holter monitoring, stress & echo

心臟科服務將包括但不限於動態心電監測、壓力和回聲。

tests, nuclear stress tests, and vascular tests. These new specialty services will be supplied by HWCC within TMC's clinics and provide a new revenue source to clinic operations.

測試、核壓力測試和血管測試。這些新的專科服務將由HWCC在TMC的診所內提供,併為診所的運營提供新的收入來源。

"By offering innovative cardiology services and testing as a specialty healthcare service, The Medi-Collective is executing on its vision of being a convenient integrated healthcare solution for patients", stated Steven McAuley, Chairman and CEO of Empower Clinics. "Patients want convenient access to Holter technology and timely results. Thanks to our partnership with Holter Health, that's exactly what they will enjoy when patients experience our integrated primary and specialty healthcare solutions at TMC. In addition to our offering of cardiology and dermatology services, we will continue to add more specialty healthcare solutions as a top priority."

Empower診所董事長兼首席執行官史蒂文·麥考利表示:“通過提供創新的心臟病學服務和作為一項專業保健服務的測試,Medi-Collective正在實現其願景,即成為患者便捷的綜合保健解決方案。”患者希望方便地獲得Holter技術和及時的結果。由於我們與Holter Health的合作伙伴關係,當患者在TMC體驗我們的綜合初級和專科醫療解決方案時,這正是他們將享受的。除了我們提供的心臟病和皮膚病服務外,我們將繼續增加更多的專科醫療解決方案作為首要任務。“

Notably Holter Health allows TMC to provide ease of access to cardiac care to patients by providing in house Holter Monitoring that is sent to some of Toronto's top Cardiologists for review and response within a week timeframe. This shortens the wait time and allows for a greater integrated clinic experience.

值得注意的是,Holter Health允許TMC通過提供內部Holter監測,在一週內發送到多倫多的一些頂級心臟病專家進行審查和反應,從而為患者提供輕鬆的心臟護理。這縮短了等待時間,並提供了更好的綜合診所體驗。

Heart Wellness Cardiac Clinics has been in diagnostic imaging and cardiology for 30 years providing echocardiograms, Holter and loop monitoring, ECGs, stress testing, stress echo, and cardiac consultations. They also provide general ultrasound and vascular technology services at 3 sites in Scarborough. HWCC has affiliated centers which provide nuclear cardiology testing without delay and are associated with Saint Michael's Hospital, Sunnybrook Health Sciences Centre and Michael Garron Hospital. HWCC counts nearly 30 health professionals including cardiologists.

心臟健康心臟診所在診斷成像和心臟病學領域已有30年的歷史,提供超聲心動圖、動態心電圖和心電監測、負荷測試、負荷回聲和心臟諮詢。他們還在斯卡伯勒的3個地點提供普通超聲波和血管技術服務。HWCC設有附屬中心,可立即提供核心髒病檢測,並與聖邁克爾醫院、桑尼布魯克健康科學中心和邁克爾·加倫醫院有聯繫。HWCC有近30名健康專業人員,其中包括心臟病專家。

Holter Health was created by HWCC to give patients easier access to an important heart-health screening tool - a holter monitor - via their family doctor, medical clinic, long-term care home, or pharmacy. Currently when a family doctor requests a holter monitor test for their patient, the patient faces a challenge to access the test via the closest cardio clinic or hospital. Holter Health provides ease of access to patients via their local medical clinic, long-term care home, or pharmacy to get their holter monitor test with proper training & support and the results sent to the patient's family doctor within a week of completing the test.

Holter Health是由HWCC創建的,旨在讓患者更容易通過家庭醫生、醫療診所、長期療養院或藥房獲得重要的心臟健康篩查工具-Holter監護儀。目前,當家庭醫生要求為他們的患者進行Holter監護儀測試時,患者面臨着通過最近的心臟診所或醫院進行測試的挑戰。Holter Health為患者提供通過當地醫療診所、長期療養院或藥店進行Holter監護儀測試的便利途徑,並在完成測試後一週內將結果發送給患者的家庭醫生。

"Heart Wellness Cardiac Centres (HWCC) and Holter Health are excited to be partnering with Empower's TMC (The Medi-Collective) clinics to expand on their 'full-service' medical services by offering full-service cardiac imaging and cardiac care services within their existing primary care clinics", said Andre Sabongui, CEO of HWCC. "This new partnership will provide TMC patients with the highest level of care and expedited referrals to necessary specialists and required diagnostic imaging testing services."

心臟健康心臟中心(HWCC)和Holter Health很高興能與Empower的TMC(醫療集體)診所合作,通過在現有的初級保健診所提供全方位的心臟成像和心臟護理服務來擴大他們的‘全方位’醫療服務,HWCC首席執行官安德烈·薩本吉説。這一新的夥伴關係將為TMC患者提供最高水平的護理和快速轉介至必要的專家和所需的診斷成像測試服務。“

Cardiology consultations is the second specialty healthcare service launched by TMC. In March 2021 TMC partnered with MedX ( to offer teledermatology services throughout its clinics. Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care - patient screening, assessment, and diagnosis - eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, TMC uses MedX's DermSecure™ Screening Platform to offer high-resolution image capture technology for moles, lesions, and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.

心臟病諮詢是TMC推出的第二項專業醫療服務。2021年3月,TMC與MedX()合作,在其所有診所提供遠程皮膚病服務。遠程皮膚科是皮膚科的一個子專業,它提供安全有效的虛擬護理--患者篩查、評估和診斷--消除了與皮膚科醫生面對面預約的需要。與其他可用的遠程皮膚病篩查工具不同,TMC使用MedX的DermSecure™篩查平臺為痣、皮損和其他皮膚狀況提供高分辨率圖像捕獲技術,在短短72小時內由認證皮膚科醫生提供完整的虛擬皮膚病評估。

"MedX is delighted to have partnered with Empower's TMC clinics as the dermatology platform of choice for their growing medical services offering. At a time when access to dermatologists remains a challenge for the Canadian patient, the early detection of skin cancer and timely access to care is critical to a successful patient outcome. We are proud to work with The Medi-Collective in providing the highest level of care to patients who need it most," said MedX CEO Naman Demaghlatrous.

MedX很高興能與Empower的TMC診所合作,成為他們日益增長的醫療服務的首選皮膚科平臺。在皮膚科醫生仍然是加拿大患者面臨的挑戰之際,皮膚癌的早期發現和及時獲得護理對患者的成功至關重要。我們很自豪能與Medi-Collective合作,為最需要的患者提供最高水平的護理。MedX首席執行官納曼·德馬格拉圖斯説。

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management

本新聞稿可在AGORACOM上的授權診所驗證論壇上獲得,以供股東討論、提問和與管理層接觸

ABOUT EMPOWER:

關於授權:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

Empower是一家綜合性醫療保健公司,通過其診所、數字和遠程醫療護理、醫療設備公司和世界級醫療診斷實驗室為患者提供身心健康。在經驗豐富的領導團隊的支持下,Empower正在北美地區積極擴大其臨牀和數字業務。我們的健康與健康和診斷與技術業務部門將積極影響我們患者的整體健康,同時為我們的股東提供長期價值。

ON BEHALF OF THE BOARD OF DIRECTORS:

我謹代表董事會:

Steven McAuley
Chief Executive Officer

史蒂文·麥考利
首席執行官

CONTACTS:

聯繫人:

Media:
Steven McAuley CEO
s.mcauley@empowerclinics.com
+1 855-855-9058

媒體:
史蒂文·麥考利首席執行官
郵箱:s.mcauley@empower Clinics.com
+1 855-855-9058

Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
+1 855-855-9058

投資者:
塔瑪拉·梅森
業務發展與溝通
郵箱:t.mason@empower Clinics.com
+1 855-855-9058

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

對前瞻性陳述的免責聲明

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. Statements other than statements of historical fact are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release, and include statements regarding the Company's ability to positively impact the integrated health of its patients while simultaneously providing long term value for shareholders. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that wait times for cardiology services will be significantly reduced, that the Company's products may not work as expected; that the Company may not be able to maintain or expand its current COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with any proposed transactions; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

本新聞稿包含適用於加拿大證券法的某些“前瞻性陳述”或“前瞻性信息”(統稱為“前瞻性陳述”)。除歷史事實陳述外,其他陳述均為前瞻性陳述,以本新聞稿發佈之日的預期、估計和預測為基礎,包括有關該公司在為股東提供長期價值的同時,積極影響患者整體健康的能力的陳述。前瞻性表述常常可以用“計劃”、“繼續”、“預期”、“項目”、“打算”、“相信”、“預期”、“估計”、“可能”、“將”、“潛在”、“建議”和其他類似詞語,或某些事件或條件“可能”或“將”發生的信息來識別。此類陳述只是預測,基於管理層目前已知的假設,受風險和不確定因素影響,可能導致實際結果、業績或發展與前瞻性陳述中包含的內容大不相同,這些風險和不確定性包括:等待心臟病服務的時間將大幅縮短,公司的產品可能無法按預期工作;公司可能無法維持或擴大目前的“新冠肺炎”檢測;法規變化可能對公司的業務和產品開發產生不利影響;公司可能無法獲得足夠的資金來實施其業務計劃;一般商業、經濟、競爭、政治和社會方面的不確定性;任何擬議交易未能獲得任何必要的批准;以及公司無法控制的其他因素。不能保證前瞻性陳述中預期的任何事件將會發生,或者如果它們確實發生了, 公司將從他們那裏獲得什麼好處。告誡讀者不要過度依賴本新聞稿中的前瞻性陳述,這些前瞻性陳述完全受這些警告性陳述的限制。除適用法律明確要求外,公司沒有義務更新或修改本新聞稿中的任何前瞻性陳述,除非適用法律明確要求,無論是新信息、未來事件還是其他原因。

SOURCE: Empower Clinics Inc.

資料來源:Empower Clinics Inc.


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論